[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

@BPharmCatalyst "$RAPP announced that its lead candidate RAP-219 met primary and key secondary endpoints in a Phase 2a trial for drug-resistant focal onset seizures demonstrating a XXXX% median seizure reduction and XX% seizure freedom with strong safety and tolerability. $DNTH $SMMT $IDYA $SINT $EDAP $XAIR See More Pre-market Movers"
X Link @BPharmCatalyst 2025-09-08T12:40Z 30.4K followers, 3558 engagements

"BioPharmCatalyst Weekly #Watchlist BioPharmCatalyst Weekly Watchlist: Key PDUFA and regulatory catalysts for the next X months $COGT $RZLT $DVBT $BLTE $MBRX $IMVT $PCVX $BCTX $KALV $CGEM"
X Link @BPharmCatalyst 2025-10-11T14:18Z 30.4K followers, 1850 engagements

"$XCUR 's GPC-100 study for stem-cell mobilization in multiple myeloma patients completed its Phase X with topline data expected in Q4 2025. Its fast dosing could simplify logistics with plans for AML and partnerships in cell/gene therapy. See More Biotech Updates👇 $FDMT $TNON $NRSN $BTAI $IMAB $BIO $XCUR $AVTR"
X Link @BPharmCatalyst 2025-08-01T20:40Z 30.4K followers, 2018 engagements

"$SPRB shares closed up after the FDA granted Breakthrough Therapy designation to tralesinidase alfa for Sanfilippo Syndrome Type B a rare pediatric neurodegenerative disorder. The company plans to file for U.S. approval in the first quarter of 2026. $SPRB $BMEA $HUMA $TELO $LXEO $LPTX $GLTO $XBIO $EVAX $CLRB See More Biotech Updates👇"
X Link @BPharmCatalyst 2025-10-07T20:32Z 30.4K followers, 2255 engagements

"$ELUT agreed to sell its cardiac device business to Boston Scientific for $88M enabling debt elimination and a strategic shift toward its breast reconstruction-focused SimpliDerm franchise and drug-eluting pipeline aiming to improve financial stability and preserve shareholder value without dilution. $TRML $ELUT $CELU $RENB $REVB $TELO $XLO See More Biotech Updates👇 link"
X Link @BPharmCatalyst 2025-09-09T20:30Z 30.4K followers, 1881 engagements

"$CDT announced a 1-for-8 reverse stock split approved by its board aiming to enhance capital-raising flexibility as part of its strategic execution following prior shareholder authorization granted in May 2025. $BJDX $CDT $AKRO $APGE $ATHE $NGNE $TCRT $BDRX $PCSA $GTBP See More Pre-market Movers"
X Link @BPharmCatalyst 2025-10-09T12:40Z 30.4K followers, 1950 engagements

"$GNPX announced preclinical data showing its lead candidate Reqorsa (quaratusugene ozeplasmid) induced apoptosis and demonstrated strong efficacy in ALK-EML4positive non-small cell lung cancer models. The data to be presented at the AACR-NCI-EORTC Molecular Targets Conference support Reqorsas potential as a gene therapy targeting the TUSC2 tumor suppressor pathway and its use in combination with ALK inhibitors. $GNPX $SCYX $KROS $EYPT $SPRC $EVAX $DMAC $IOBT $ELAB $ENTX See More Pre-market Movers"
X Link @BPharmCatalyst 2025-10-15T12:40Z 30.4K followers, 11.6K engagements

"$NDRA secured $XXX million in a private placement led by institutional and crypto investors selling stock and warrants at $XXXX per unit to fund a digital asset treasury strategy focused on Arcas high-conviction DeFi holdings marking a pivot toward blockchain-linked capital deployment alongside its core MASLD/MASH imaging focus. $TRVD $CGEN $RCUS $MNPR $NDRA $SRRK $NBTX $APLT $QNRX $ADTX See More Biotech Updates👇"
X Link @BPharmCatalyst 2025-10-13T20:30Z 30.4K followers, 1901 engagements

"$ARMP reported topline results from its Phase 1b/2a diSArm trial which evaluated AP-SA02 a novel IV administered multi-phage therapeutic for the treatment of S. aureus bacteremia (SAB) in the ITT population. The study showed that all primary endpoints for safety tolerability and clinical response in the intent-to-treat population were met. See More Biotech Updates👇 $PTIX $CVM $RGNX $NVAX $SKYE $QNTM $GUTS $XRTX $APLT"
X Link @BPharmCatalyst 2025-05-19T20:53Z 30.4K followers, 1775 engagements

"$SPRB secured $50M in a private placement to fund advancement of tralesinidase alfa for Sanfilippo Syndrome Type B (MPS IIIB) through BLA submission in Q1 2026 targeting a potential U.S. commercial launch by late 2026. $ESPR $SPRB $KPTI $RNAZ $VRCA $RBOT $XBIO $ACXP $GLTO $BJDX See More Pre-market Movers"
X Link @BPharmCatalyst 2025-10-08T12:40Z 30.4K followers, 2971 engagements

"$EVAX will present new biomarker and immune data for its personalized cancer vaccine EVX-01 in advanced melanoma at SITC 2025 complementing upcoming two-year efficacy results from its Phase X KEYTRUDA combination trial being presented at ESMO 2025. $PALI $ANRO $OVID $IMAB $BOLT $EVAX $APLIF $CLNN $SPRC $OCEA See More Biotech Updates👇"
X Link @BPharmCatalyst 2025-10-03T20:30Z 30.4K followers, 3349 engagements